DENTSPLY SIRONA Inc. ($XRAY) Stock Forecast: Up 5.0% Today

What is DENTSPLY SIRONA Inc.?

Dentsply Sirona (XRAY) is a company operating in the Health Technology and Medical Specialties sector, known for its dental products and solutions. Today, the stock experienced a strong bullish movement in the market.

Why is DENTSPLY SIRONA Inc. going up?

XRAY stock is up 5.0% on Apr 1, 2026 15:42

• Despite negative analysis pointing out declining revenue and shaky fundamentals, the stock saw a significant bullish movement, possibly due to the increased price target, indicating a more optimistic outlook on its future performance.
• The administrative disclosure of Vanguard's 0% ownership in XRAY may have initially raised concerns, but the market sentiment seemed to have shifted positively towards the stock.
• The introduction of a new dental product by Dentsply Sirona USA may have also contributed to the bullish movement, showcasing potential for innovation and growth in the company's product line.
• Investors might be viewing the stock differently, possibly considering the potential of new investments and products to drive future growth, leading to the bullish market movement despite previous concerns.

XRAY Price Chart

XRAY Technical Analysis

XRAY News

3 Reasons to Avoid XRAY and 1 Stock to Buy Instead

This article analyzes Dentsply Sirona (XRAY) and advises investors to avoid it due to declining constant currency revenue, previous growth initiatives losing money, and new investments failing to improve its Return on Invested Capital (ROIC). The company's stock is down 9.6% over the last six months, and its valuation, while seemingly cheap, is considered risky given its shaky fundamentals. Instead, the author suggests considering "one of Charlie Munger's all-time favorite businesses" and other market-beating stocks identified by StockStory's AI platform.

https://uk.finance.yahoo.com/news/3-reasons-avoid-xray-1-202218862.html

Dentsply Sirona (XRAY) price target increased by 11.25% to 14.71

The article reports that the price target for Dentsply Sirona (XRAY) has been increased by 11.25%, bringing it to $14.71. This indicates a more optimistic outlook on the stock's future performance.

https://www.msn.com/en-us/money/topstocks/dentsply-sirona-xray-price-target-increased-by-1125-to-1471/ar-AA1ZyWPp?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1

Vanguard realignment shows 0% XRAY ownership; affiliates to report separately (XRAY)

The Vanguard Group has filed an Amendment No. 18 to a Schedule 13G/A, reporting 0 shares beneficially owned and 0% of DENTSPLY SIRONA Inc. (XRAY). This change is due to an internal realignment at Vanguard, effective January 12, 2026, which disaggregated certain subsidiaries for separate reporting in reliance on SEC Release No. 34-39538. This filing is an administrative disclosure of ownership structure, not an economic transaction, indicating that future filings from Vanguard affiliates may show redistributed holdings.

https://www.stocktitan.net/sec-filings/XRAY/schedule-13g-a-dentsply-sirona-inc-amended-passive-investment-disclos-53769a4259ae.html

DENTSPLY SIRONA, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1 Sh

This article focuses on the EBIT per share of DENTSPLY SIRONA, Inc. (XRAY34) as traded on the BMFBOVESPA exchange in Brazil. It presents a detailed view of its financial performance within the Health Technology and Medical Specialties sector. The content includes an overview, financials, news, community, technicals, and seasonals related to the company's stock.

https://www.tradingview.com/symbols/BMFBOVESPA-XRAY34/financials-statistics-and-ratios/ebit-per-share/

Tooth File Files | Dentsply Sirona USA Vortex Blue Rotary Endo

This article from Dentsply Sirona USA introduces their Vortex Blue Rotary Endo Files. The content focuses specifically on this dental product.

https://hotelier.com.py/product/Rotary-Endo-Files-Dentsply-Sirona-USA/404425

Trending Today

Virgin Galactic Holdings Inc ($SPCE) Stock Forecast: Up 5.1% Today

Alphabet Inc. ($GOOGL) Stock Forecast: Up 5.6% Today

Sunrun Inc. ($RUN) Stock Forecast: Up 7.9% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Up 8.9% Today

Saia Inc. ($SAIA) Stock Forecast: Up 5.2% Today

ConocoPhillips ($COP) Stock Forecast: Down 5.2% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Up 9.3% Today

Rockwell Automation Inc. ($ROK) Stock Forecast: Up 5.2% Today

Novavax Inc. ($NVAX) Stock Forecast: Up 5.0% Today

Plug Power Inc. ($PLUG) Stock Forecast: Up 5.4% Today

DENTSPLY SIRONA Inc. Price History

18.02.2026 - XRAY Stock was down 5.3%

• The stock price of XRAY declined despite a 5.24% increase on March 17.
• The FDA clearance for the MAGNETOM Free.Max Dental Edition, a new innovation, might not have led to immediate revenue growth, potentially disappointing investors.
• Despite increased stakes from investment firms like Invenomic Capital Management LP and Crawford Investment Counsel Inc., the stock's downward trend continues, possibly due to missed earnings expectations.
• The undervaluation of XRAY according to Simply Wall St's valuation model could offer an opportunity for investors, but market challenges and a multi-year share price slump may be contributing to the bearish movement.

24.01.2026 - XRAY Stock was up 6.7%

• A notable increase in Brickwood Asset Management LLP's ownership in DENTSPLY SIRONA suggests growing confidence in the company's future, influencing positive market outlook.
• The introduction of new webinars on implant dentistry underlines DENTSPLY SIRONA's dedication to education and advancement, potentially attracting increased interest from both dental professionals and investors.
• Bank of America's decision to raise its rating on DENTSPLY SIRONA from "neutral" to "buy" with an increased price target signals optimism about the company's performance, contributing to a rise in the stock's value. This upgrade, combined with favorable developments related to the company, likely drove today's strong upward momentum in XRAY's stock price.

19.02.2026 - XRAY Stock was down 5.1%

• The bearish movement in XRAY stock could be attributed to profit-taking by investors after a recent uptick in the stock price.
• Despite positive sentiments from analysts and figures like Jim Cramer, the market may have reacted negatively to the uncertainty surrounding the immediate revenue impact of the newly FDA-cleared dental MRI technology.
• The filing of 13G by Southpoint indicating a significant ownership stake in Dentsply Sirona might have also influenced market sentiment, leading to some selling pressure on the stock.
• Investors might be cautious about the company's ability to navigate existing market challenges and translate innovative technologies like the dental-dedicated MRI system into tangible revenue growth in the short term.

19.01.2026 - XRAY Stock was down 6.4%

• Significant reductions in stakes were observed from Heartland Advisors Inc. and Cibc World Market Inc. in DENTSPLY SIRONA Inc., likely influencing the bearish market movement.
• Analysts are expressing pessimism towards XRAY, indicating lowering price targets and prevailing "Reduce" ratings possibly intensifying the stock's downward trend.
• Director Gregory T. Lucier's insider selling activity could have played a role in denting investor confidence in the company, contributing to the prevailing bearish sentiment.
• Despite an increase in stock holdings by Advisors Asset Management Inc., the general caution exhibited by analysts and the consistent insider selling activities suggest ongoing apprehension about DENTSPLY SIRONA Inc.'s future performance, potentially accentuating the bearish market movement.

20.01.2026 - XRAY Stock was down 5.6%

• Despite receiving a "buy" rating and a price target raise to $17 from an analyst, DENTSPLY SIRONA observed a notable decline in its stock value, indicating a potential divergence in market response.
• Insider selling activities by Heartland Advisors Inc. and Director Gregory T. Lucier, in addition to reduced holdings by Cibc World Market Inc., might have influenced the bearish movement by sparking concerns among investors regarding the company's future prospects.
• The prevailing negative analyst outlook, with a consensus rating of "Reduce" and an average price target of $14.25, could have outweighed the positive impact of the upgrade, leading to downward pressure on the stock.
• The blend of diverse analyst feedback, insider sell-offs, and market sentiment could have set a backdrop where the positive news of the upgrade got overshadowed by other factors, resulting in the stock's bearish trajectory for DENTSPLY SIRONA.

27.01.2026 - XRAY Stock was up 11.2%

• DENTSPLY SIRONA's bullish movement could be attributed to the company's updated earnings guidance for FY 2026, despite falling slightly short on revenue projections. The market seems to have reacted positively to the overall outlook.
• The release of Q4 2025 earnings, where the company exceeded revenue estimates, might have contributed to the stock rise, outweighing the slight miss on earnings per share.
• The appointment of new experienced members to the Board of Directors, with a focus on financial rigor and operational performance, could have instilled confidence in investors, leading to the bullish trend.
• Despite some shareholder concerns and investigations into corporate governance practices, the strategic changes within the company's leadership structure appear to have resonated well with the market, driving the stock price up.

01.03.2026 - XRAY Stock was up 5.0%

• Despite negative analysis pointing out declining revenue and shaky fundamentals, the stock saw a significant bullish movement, possibly due to the increased price target, indicating a more optimistic outlook on its future performance.
• The administrative disclosure of Vanguard's 0% ownership in XRAY may have initially raised concerns, but the market sentiment seemed to have shifted positively towards the stock.
• The introduction of a new dental product by Dentsply Sirona USA may have also contributed to the bullish movement, showcasing potential for innovation and growth in the company's product line.
• Investors might be viewing the stock differently, possibly considering the potential of new investments and products to drive future growth, leading to the bullish market movement despite previous concerns.

26.02.2026 - XRAY Stock was up 5.5%

• Anticipated weaker earnings by Zacks Research contrast with the launch of the new Vortex Blue Rotary Endo Files by DENTSPLY SIRONA, likely boosting investor confidence in the company's future offerings.
• Diverse analyst opinions and recent financial results may have led to stock price instability, partially offset by insider purchases indicating internal positivity and influencing investor optimism.
• The stock's bullish momentum today might be attributed to investors focusing on the growth potential of the new product rather than short-term earnings, potentially propelling the stock price upwards.

13.02.2026 - XRAY Stock was down 6.0%

• The significant bearish movement in Dentsply Sirona's stock (XRAY) today can be attributed to the company's alarming 63% collapse in free cash flow in 2025, leading to a restructuring plan and dividend elimination to focus on debt reduction and share repurchases.
• The cautious 2026 outlook, weak U.S. sales, and rising tariff costs have added to investor concerns, despite efforts towards operational streamlining and cost reduction programs to enhance EBITDA margins and cash flow.
• The increased stakes by major institutional investors like Gamco Investors and American Century Companies signal confidence in Dentsply Sirona's long-term prospects, but the mixed analyst sentiment and ongoing risks, especially in the Chinese market, are contributing to the stock's downward trajectory.

17.02.2026 - XRAY Stock was up 5.9%

• The positive market sentiment surrounding the FDA clearance for the MAGNETOM Free.Max Dental Edition may have influenced the bullish movement in XRAY's stock today, showcasing the company's dedication to innovation in the dental industry.
• Increased investments by notable entities like Invenomic Capital Management LP and company insiders purchasing shares could have boosted market confidence, indicating a positive outlook for XRAY's future performance.
• Despite recent earnings falling below expectations and a decline in share price over several years, the belief that XRAY is undervalued and the growth prospects in the dental sector may have attracted investor attention, contributing to the stock's bullish performance today.
• The accumulation of favorable developments in innovation, heightened investor confidence, and the perceived undervaluation could have collectively driven XRAY's strong bullish performance in the market today.

12.02.2026 - XRAY Stock was down 5.3%

• Dentsply Sirona (XRAY) shares plummeted due to an earnings miss, significant impairment charges, and a cautious 2026 outlook, despite higher Q4 sales, leading to investor concerns about the company's future performance.
• The increased stake by Gamco Investors and American Century Companies Inc. might indicate confidence in the long-term prospects of Dentsply Sirona, but the overall market sentiment remains cautious.
• The insider stock purchases by Director Gregory Lucier could be seen as a positive sign, but the mixed analyst ratings and the company's challenges, such as weak U.S. sales and rising tariff costs, are contributing to the downward pressure on the stock.
• Investors are advised to closely monitor the company's cost reduction programs and operational streamlining efforts to gauge its potential recovery and assess the impact of external factors on its financial performance.

03.02.2026 - XRAY Stock was down 5.9%

• The company's stock witnessed a significant bearish trend, despite recent announcements of a strategic Q4 earnings report and a restructuring initiative focused on cost savings, debt reduction, and stock repurchases.
• Investors seemed more concerned about DENTSPLY SIRONA's below-expectation guidance for 2026, overshadowing the positive revenue results in Q4.
• The initial stock price increase post-restructuring may have been short-lived, with market participants reacting negatively to the cautious outlook for the upcoming year.
• Despite the encouraging news of the restructuring and revenue performance, the failure to meet profit forecasts and the conservative guidance for 2026 likely influenced investor sentiment, contributing to the bearish market movement.